Schemionek, M.Elling, C.Steidl, U.Baumer, N.Hamilton, A.Spieker, T.Gothert, J. R.Stehling, M.Wagers, AmyHuettner, Claudia SonjaTenen, DanielTickenbrock, L.Berdel, W. E.Serve, H.Holyoake, T. L.Muller-Tidow, C.Koschmieder, S.2017-07-072010Schemionek, M., C. Elling, U. Steidl, N. Baumer, A. Hamilton, T. Spieker, J. R. Gothert, et al. 2010. “BCR-ABL Enhances Differentiation of Long-Term Repopulating Hematopoietic Stem Cells.” Blood 115 (16) (January 6): 3185–3195. doi:10.1182/blood-2009-04-215376.0006-4971http://nrs.harvard.edu/urn-3:HUL.InstRepos:33158473In a previously developed inducible transgenic mouse model of chronic myeloid leukemia, we now demonstrate that the disease is transplantable using BCR-ABL+ Lin−Sca-1+c-kit+ (LSK) cells. Interestingly, the phenotype is more severe when unfractionated bone marrow cells are transplanted, yet neither progenitor cells (Lin−Sca-1−c-kit+), nor mature granulocytes (CD11b+Gr-1+), nor potential stem cell niche cells (CD45−Ter119−) are able to transmit the disease or alter the phenotype. The phenotype is largely independent of BCR-ABL priming before transplantation. However, prolonged BCR-ABL expression abrogates the potential of LSK cells to induce full-blown disease in secondary recipients and increases the fraction of multipotent progenitor cells at the expense of long-term hematopoietic stem cells (LT-HSCs) in the bone marrow. BCR-ABL alters the expression of genes involved in proliferation, survival, and hematopoietic development, probably contributing to the reduced LT-HSC frequency within BCR-ABL+ LSK cells. Reversion of BCR-ABL, or treatment with imatinib, eradicates mature cells, whereas leukemic stem cells persist, giving rise to relapsed chronic myeloid leukemia on reinduction of BCR-ABL, or imatinib withdrawal. Our results suggest that BCR-ABL induces differentiation of LT-HSCs and decreases their self-renewal capacity.en-USJournal Article10.1182/blood-2009-04-215376